The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: Long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801

Lung Cancer

Volumn 80, Issue 3, 2013, Pages 298-305

  Lawrence, Yaacov Richard ^a,d   Paulus, Rebecca ^b   Langer, Corey ^c   Werner Wasik, Maria ^d   Buyyounouski, Mark K ^e   Komaki, Ritsuko ^f   Machtay, Mitchell ^g   Smith, Colum ^h,j   Axelrod, Rita S ^d   Wasserman, Todd ⁱ   Bradley, Jeffrey D ⁱ   Movsas, Benjamin ^k  

^a SHEBA MEDICAL CENTER   (Israel)

^b RTOG Statistical Center   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h TOM BAKER CANCER CENTRE   (Canada)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j SASKATCHEWAN CANCER AGENCY   (Canada)

^k HENRY FORD HOSPITAL   (United States)

more..

Author keywords

Amifostine; Carboplatin; Chemoradiation; Non small cell lung cancer; NSCLC; Paclitaxel

Indexed keywords

AMIFOSTINE; CARBOPLATIN; PACLITAXEL;

ADVANCED CANCER; ARTICLE; BONE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESOPHAGUS DISEASE; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; SPINAL CORD DISEASE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL;

EID: 84877148192     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.02.008     Document Type: Article

References (48)

1. Auperin A., Le Pechoux C., Rolland E., Curran W.J., Furuse K., Fournel P., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2181-2190.
2. Komaki R., Scott C.B., Sause W.T., Johnson D.H., Taylor S.G.T., Lee J.S., et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1997, 39:537-544.
3. Stewart L. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995, 311:899-909.
4. Rowell N.P., O'rourke N.P. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004, CD002140.
5. Curran W.J., Paulus R., Langer C.J., Komaki R., Lee J.S., Hauser S., et al. Sequential vs. concurrent chemoradiation for stage III non small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011, 103:1452-1460.
6. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999, 17:2692-2699.
7. Vokes E.E., Herndon J.E., Kelley M.J., Cicchetti M.G., Ramnath N., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007, 25:1698-1704.
8. Movsas B. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group Trial 98-01. J Clin Oncol 2005, 23:2145-2154.
9. Sarna L., Swann S., Langer C., Wernerwasik M., Nicolaou N., Komaki R., et al. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys 2008, 72:1378-1384.
10. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 457-481.
11. Pike M.C. Asymptomatically efficient rank invariant procedures. JR Stat Soc Series A 1972, 135:201-203.
12. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
13. Kouvaris J.R., Kouloulias V.E., Vlahos L.J. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 2007, 12:738-747.
14. Antonadou D., Coliarakis N., Synodinou M., Athanassiou H., Kouveli A., Verigos C., et al. Randomized phase III trial of radiation treatment±amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 2001, 51:915-922.
15. Brizel D.M., Wasserman T.H., Henke M., Strnad V., Rudat V., Monnier A., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000, 18:3339-3345.
16. Buentzel J., Micke O., Adamietz I.A., Monnier A., Glatzel M., de Vries A. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 2006, 64:684-691.
17. Wasserman T.H., Brizel D.M., Henke M., Monnier A., Eschwege F., Sauer R., et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and-neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 2005, 63:985-990.
18. Bourhis J., Blanchard P., Maillard E., Brizel D.M., Movsas B., Buentzel J., et al. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. J Clin Oncol 2011, 29:2590-2597.
19. Movsas B., Moughan J., Komaki R., Choy H., Byhardt R., Langer C., et al. Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol 2003, 21:4553-4559.
20. Auperin A. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 2006, 17:473-483.
21. Mitchell M., Chuanchieh H., Ritsuko K., William T.S., Swann R.S., Corey J.L., et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys 2005, 63:667-671.
22. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
23. Eileen R., May T., Yee U., Jean-Philippe P., Patrick C., Edward C. Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non small-cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys 2004, 58:196-203.
24. O'Rourke N., Roque i Figuls M., Farre Bernado N., Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010, 6.
25. Wang L., Wu S., Ou G., Bi N., Li W., Ren H., et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 2012, 77:89-96.
26. Yamamoto N., Nakagawa K., Nishimura Y., Tsujino K., Satouchi M., Kudo S., et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 2010, 28:3739-3745.
27. Segawa Y., Kiura K., Takigawa N., Kamei H., Harita S., Hiraki S., et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 2010, 28:3299-3306.
28. Curran W., Scott C., Langer C., Komaki R., Lee R., Hauser J., et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III nsclc: RTOG 9410. Proc Am Soc Clin Oncol 2003, 22. (abstract 2499).
29. Hanna N., Neubauer M., Yiannoutsos C., Mcgarry R., Arseneau J., Ansari R., et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008, 26:5755-5760.
30. Vokes E.E., Herndon J.E., Crawford J., Leopold K.A., Perry M.C., Miller A.A.M.R.G. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol 2002, 20:4191-4198.
31. Zatloukal P., Petruzelka L., Zemanova M., Havel L., Janku F., Judas L., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004, 46:87-98.
32. Stinchcombe T.E., Hodgson L., Herndon J.E., Kelley M.J., Cicchetti M.G., Ramnath N., et al. Treatment outcomes of different prognostic groups of patients on cancer and Leukemia Group B Trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol 2009, 4.
33. Mauguen A., Le Pechoux C., Saunders M.I., Schild S.E., Turrisi A.T., Baumann M., et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 2012, 30:2788-2797.
34. Fischer B., Lassen U., Mortensen J., Larsen S., Loft A., Bertelsen A., et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009, 361:32-39.
35. Chen A.B., Neville B.A., Sher D.J., Chen K., Schrag D. Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. J Clin Oncol 2011, 29:2305-2311.
36. Movsas B., Moughan J., Sarna L., Langer C., Werner-Wasik M., Nicolaou N., et al. Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol 2009, 27:5816-5822.
37. Jeremic B., Shibamoto Y., Acimovic L., Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995, 13:452-458.
38. Komaki R., Seiferheld W., Ettinger D., Lee J.S., Movsas B., Sause W. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. Int J Radiat Oncol Biol Phys 2002, 53:548-557.
39. Clamon G., Herndon J., Cooper R., Chang A.Y., Rosenman J., Green M.R. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999, 17:4-11.
40. Jeremic B., Shibamoto Y., Acimovic L., Milicic B., Milisavljevic S., Nikolic N., et al. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 2001, 50:19-25.
41. Schild S.E., Stella P.J., Geyer S.M., Bonner J.A., Marks R.S., McGinnis W.L., et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002, 54:370-378.
42. Fournel P. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005, 23:5910-5917.
43. Belani C.P., Choy H., Bonomi P., Scott C., Travis P., Haluschak J., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005, 23:5883-5891.
44. Belderbos J., Uitterhoeve L., van Zandwijk N., Belderbos H., Rodrigus P., van de Vaart P., et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 2007, 43:114-121.
45. Yuan S., Sun X., Li M., Yu J., Ren R., Yu Y., et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 2007, 30:239-244.
46. Thomas M., Rübe C., Hoffknecht P., Macha H.N., Freitag L., Linder A., et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 2008, 9:636-648.
47. Kelly K., Chansky K., Gaspar L.E., Albain K.S., Jett J., Ung Y.C., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008, 26:2450-2456.
48. Hoang T., Dahlberg S.E., Schiller J.H., Mehta M.P., Fitzgerald T.J., Belinsky S.A., et al. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. J Clin Oncol 2012, 30:616-622.